TETTAMANTI, SARAH
 Distribuzione geografica
Continente #
NA - Nord America 2.857
AS - Asia 1.847
EU - Europa 1.820
SA - Sud America 304
AF - Africa 49
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.888
Nazione #
US - Stati Uniti d'America 2.757
SG - Singapore 693
IT - Italia 659
CN - Cina 436
BR - Brasile 255
HK - Hong Kong 236
RU - Federazione Russa 230
DE - Germania 224
IE - Irlanda 188
VN - Vietnam 161
SE - Svezia 134
GB - Regno Unito 94
CA - Canada 72
IN - India 69
ID - Indonesia 63
FR - Francia 53
FI - Finlandia 39
PL - Polonia 34
KR - Corea 33
ZA - Sudafrica 28
JP - Giappone 27
NL - Olanda 25
ES - Italia 23
AT - Austria 22
TR - Turchia 22
PK - Pakistan 21
MX - Messico 20
UA - Ucraina 20
AR - Argentina 16
BE - Belgio 15
BD - Bangladesh 14
DK - Danimarca 13
IQ - Iraq 12
IR - Iran 12
CH - Svizzera 10
RO - Romania 8
AU - Australia 7
IL - Israele 7
LT - Lituania 7
TW - Taiwan 7
EG - Egitto 6
NP - Nepal 6
PE - Perù 6
CZ - Repubblica Ceca 5
EC - Ecuador 5
KZ - Kazakistan 5
MA - Marocco 5
PH - Filippine 5
CI - Costa d'Avorio 4
CL - Cile 4
CO - Colombia 4
NO - Norvegia 4
PY - Paraguay 4
RS - Serbia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
JM - Giamaica 3
LB - Libano 3
UY - Uruguay 3
UZ - Uzbekistan 3
AM - Armenia 2
BO - Bolivia 2
DZ - Algeria 2
HR - Croazia 2
KE - Kenya 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PA - Panama 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
RE - Reunion 1
TH - Thailandia 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.888
Città #
Ann Arbor 429
Singapore 425
Ashburn 390
Hong Kong 233
Milan 213
Chandler 186
Dublin 182
Frankfurt am Main 129
Fairfield 114
New York 99
Los Angeles 83
Wilmington 78
Beijing 77
Seattle 76
Hefei 72
Dallas 69
Houston 67
Woodbridge 62
Santa Clara 59
Ho Chi Minh City 57
Jakarta 51
Shanghai 48
Cambridge 47
Bergamo 42
Denver 39
Princeton 37
The Dalles 37
Hanoi 32
Munich 32
São Paulo 31
Buffalo 30
Montreal 30
Chicago 29
Dearborn 28
Seoul 27
Tokyo 25
Lissone 22
Nanjing 22
Warsaw 22
Johannesburg 21
Moscow 20
Orem 19
Poplar 16
Altamura 15
Brussels 15
Helsinki 15
London 15
Stockholm 15
Paris 14
Lawrence 13
Monza 13
Rome 13
Brooklyn 12
Lappeenranta 12
Vienna 12
Atlanta 11
Borgomanero 11
Desio 11
Genoa 11
Jacksonville 11
Lahore 11
Manchester 11
Mumbai 11
Nuremberg 11
Toronto 11
Turin 11
Ankara 10
Carate Brianza 10
Carrboro 10
Cinisello Balsamo 10
Council Bluffs 10
Hyderabad 10
Seregno 10
Boston 9
Turku 9
Andover 8
Bologna 8
Chennai 8
Fremont 8
Kent 8
Phoenix 8
Belo Horizonte 7
Brasília 7
Hangzhou 7
Mexico City 7
Ottawa 7
Wroclaw 7
Brescia 6
Düsseldorf 6
Galliate 6
Guangzhou 6
Jinan 6
Missaglia 6
Naples 6
New Delhi 6
Rio de Janeiro 6
San Francisco 6
Zhengzhou 6
Calgary 5
Charlotte 5
Totale 4.346
Nome #
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 393
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 370
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 354
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 348
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy 342
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 303
Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going? 293
CXCR4-MODIFIED CD33.CAR-CIK WITH ENHANCED BONE MARROW HOMING IN ACUTE MYELOID LEUKEMIA 274
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden 233
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 225
Catch me if you can: how AML and its niche escape immunotherapy 221
Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use 220
Overexpression of CXCR4 receptor on CD33.CAR-CIK cells enhances the control of the Acute Myeloid Leukemia burden 210
Update on: proteome analysis in thyroid pathology - part II: overview of technical and clinical enhancement of proteomic investigation of the thyroid lesions 209
Cellule CD33.CAR-CIK ingegnerizzate per co-esprimere il recettore CXCR4 al fine di aumentare la capacità di migrazione all’interno della nicchia midollare nella leucemia mieloide acuta 202
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 201
Combining the Expression of CD33.CAR and CXCR4 to Increase CAR-CIK Cell Homing to Bone Marrow Niche and Leukemic Stem Cell Eradication in Acute Myeloid Leukemia 201
Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions 196
Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia 192
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response 189
Combining the expression of CD33.CAR and CXCR4 to augment CAR-CIKs homing to bone marrow niche and leukemic stem cell eradication in acute myeloid leukemia 186
IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML 182
Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche 174
Generation of CIK cells co-expressing CXCR4 and CD33.CAR with improved homing and antitumor activity for AML 173
Optimized GMP-grade production of non-viral Sleeping Beauty-generated CARCIK cells for enhanced fitness and clinical scalability 172
CARs are sharpening their weapons 166
Improving Bone Marrow Homing and Persistence of CD33.CAR-CIK Cells By Overexpression of a Gain-of-Function Variant of CXCR4 to Increase Efficacy in Acute Myeloid Leukemia 163
The management of haemoglobin interference for the MALDI-MSI analysis of in-vivo thyroid biopsies 158
Ingegnerizzazione di cellule CD33.CAR-CIK con una variante gain-of-function del recettore CXCR4 per aumentarne migrazione e persistenza nella nicchia midollare 138
Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies 137
Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab 133
Acute Myeloid Leukemia (AML) immunotherapy: development of TIM3-CD33 targeted Dual CAR CIK cells for eradication of LSCs in the bone marrow niche 122
Totale 7.080
Categoria #
all - tutte 22.505
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.505


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021293 0 0 0 0 0 62 39 46 33 43 29 41
2021/2022335 23 33 22 18 20 18 11 15 24 32 24 95
2022/2023703 91 164 69 65 16 93 19 51 49 4 58 24
2023/2024723 31 29 45 59 72 171 117 46 59 19 14 61
2024/20251.639 62 111 134 65 109 103 125 74 150 247 165 294
2025/20262.508 569 249 315 617 618 140 0 0 0 0 0 0
Totale 7.080